Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.

ABSTRACT: The present study is the first phase II clinical trial aimed to evaluate the efficacy and safety of S-1 plus nanoparticle albumin-bound paclitaxel (Nab-PTX) as first-line chemotherapy for advanced gastric cancer (AGC). Previously untreated patients with metastatic gastric adenocarcinoma received S-1 in oral doses of 40 mg (BSA <1.25 m² ), 50 mg (1.25 ≤ BSA < 1.50 m² ) and 60 mg (BSA ≥1.50 m² ) b.i.d. on days 1-14 in combination with Nab-PTX (120 mg/m² , on days 1 and 8) for each 21-day cycle. Primary endpoint was progression-free survival (PFS), and secondary endpoints were overall response rate (ORR), overall survival (OS), disease control rate (DCR), and toxicity. A total of 73 gastric cancer patients with metastatic and measurable lesions were

SUBMITTER: He MM 

PROVIDER: S-EPMC6215885 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature